What does [TIMP-2]x[IGFBP7] measure?

[TIMP-2]x[IGFBP7] measures tubular cell cycle arrest markers. Elevated levels indicate tubular cells have arrested in G1 phase, predicting AKI within 12 hours of ICU admission.

What threshold guides clinical intervention?

Value >=2.0 (ng/mL)^2/1000 identifies highest AKI risk (>35% probability of KDIGO stage 2-3 AKI). KDIGO care bundle (stop nephrotoxins, optimize hemodynamics, avoid contrast) is indicated.

Is [TIMP-2]x[IGFBP7] FDA approved?

Yes. NephroCheck (Astute Medical) received FDA 510(k) clearance in 2014 for predicting moderate-severe AKI risk in ICU patients within 12 hours.

TIMP-2 IGFBP7 Product AKI Prediction

Calculate the [TIMP-2] x [IGFBP7] product (NephroCheck) for AKI risk assessment. Value >0.3 (ng/mL)^2/1000 predicts moderate-severe AKI within 12 hours with AUC 0.80.

Use the full interactive calculator below, or

Related Calculators

NGAL AKI Timing

Hyper-niche Medical

KIM-1 AKI Biomarker

Hyper-niche Medical

KDIGO AKI Stage ATN vs Prerenal

Hyper-niche Medical

TIMP-2 IGFBP7 Product AKI Prediction

Related Calculators

Frequently Asked Questions

What does [TIMP-2]x[IGFBP7] measure?

What threshold guides clinical intervention?

Is [TIMP-2]x[IGFBP7] FDA approved?